Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.

Glucose-lowering drugs, Metabolic dysfunction-associated fatty liver disease, Non-alcoholic fatty liver disease, Type 2 diabetes mellitus

10.3350/cmh.2022.0015

2287-2728

725-738

Miao, Lei

965e629f-454b-4d67-b239-78fbf1873275

Xu, Jing

1274e669-2f05-4848-849e-de7ad2636cec

Targher, Giovanni

119a42ae-1245-42c7-8644-9881fadcd76e

Byrne, Christopher

1370b997-cead-4229-83a7-53301ed2a43c

Zheng, Ming-Hua

cc3ddc1b-7fb7-43ab-a4bd-8134c289bca8

14 March 2022

Miao, Lei

965e629f-454b-4d67-b239-78fbf1873275

Xu, Jing

1274e669-2f05-4848-849e-de7ad2636cec

Targher, Giovanni

119a42ae-1245-42c7-8644-9881fadcd76e

Byrne, Christopher

1370b997-cead-4229-83a7-53301ed2a43c

Zheng, Ming-Hua

cc3ddc1b-7fb7-43ab-a4bd-8134c289bca8

Miao, Lei, Xu, Jing, Targher, Giovanni, Byrne, Christopher and Zheng, Ming-Hua (2022) Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review. Clinical and Molecular Hepatology, 28 (4), 725-738. (doi:10.3350/cmh.2022.0015).

Record type: Review

Abstract

Text

Manuscript_R1 - Accepted Manuscript

Available under License Creative Commons Attribution.

Download (423kB)

Text

Table 1 - Accepted Manuscript

Available under License Creative Commons Attribution.

Download (191kB)

Text

Table 2 - Accepted Manuscript

Available under License Creative Commons Attribution.

Download (172kB)

Image

Figure 1 - Accepted Manuscript

Restricted to Repository staff only

Request a copy

Image

Figure 2 - Accepted Manuscript

Restricted to Repository staff only

Request a copy

Image

Figure 3 - Accepted Manuscript

Restricted to Repository staff only

Request a copy

Show all 6 downloads.

More information

Accepted/In Press date: 11 March 2022

e-pub ahead of print date: 14 March 2022

Published date: 14 March 2022

Additional Information: Funding Information: This work was supported by grants from the National Natural Science Foundation of China (No. 82070588), High Level Creative Talents from the Department of Public Health in Zhejiang Province (No. S2032102600032), Project of New Century 551 Talent Nurturing in Wenzhou. GT is supported in part by grants from the University School of Medicine of Verona, Verona, Italy. CDB is supported in part by the Southampton NIHR Biomedical Research Centre (IS-BRC-20004), UK. This work is a part of the PERSONS study. Funding Information: This work was supported by grants from the National Natural Science Foundation of China (No. 82070588), High Level Creative Talents from the Department of Public Health in Zhejiang Province (No. S2032102600032), Project of New Century 551 Talent Nurturing in Wenzhou. GT is supported in part by grants from the University School of Medicine of Ve-rona, Verona, Italy. CDB is supported in part by the Southampton NIHR Biomedical Research Centre (IS-BRC-20004), UK. This work is a part of the PERSONS study. Publisher Copyright: © 2022 by Korean Association for the Study of the Liver.

Keywords: Glucose-lowering drugs, Metabolic dysfunction-associated fatty liver disease, Non-alcoholic fatty liver disease, Type 2 diabetes mellitus